Cardax Inc.’s revenue nearly tripled in the first quarter as its new anti-inflammatory product continued to gain widespread acceptance.

The Honolulu-based company, which launched ZanthoSyn in August 2016, generated $313,310 in sales during the January-March period compared with $107,990 in the year-earlier quarter.

“ZanthoSyn is experiencing robust market acceptance among both health care professionals and consumers, driven by successful execution of our sales and marketing strategy by our team,” Cardax President and CEO David Watumull said Wednesday in a statement.

Cardax said sales are accelerating not only in Hawaii but also California and Nevada, and that for the second straight quarter ZanthoSyn was the top-selling product at General Nutrition Corp. stores in the islands. The company said its sales and marketing strategy includes physician outreach and education, and GNC store outreach, education and in-store sales support. Cardax said its results also include the company’s initial sales of $16,413 to its Chinese distributor, Health Elite Club Ltd. of Hong Kong.

The company, which has not had a profitable quarter yet because of increasing expenses associated with the research and launch of its product, saw its loss widen in the first quarter to just over $1 million from a loss of $450,836 in the year-earlier period. Since inception in March 2010, the company has had a loss of about $59 million.

Last quarter, Cardax’s operating expenses more than doubled to $1.2 million from $516,138 as sales and marketing more than quadrupled to $350,114 and general administrative expenses more than doubled to $553,269.

Cardax’s stock was unchanged Wednesday at 29 cents. The company released its results before the market opened.